SLIDE 1
Abstract Session A3: Health Disparities/Vulnerable Populations
Moderators: Gail Daumit, MD, MHS and Monica E. Peek, MD, MPH
**This session is one of two piloting a short abstract presentation style** ILLICIT BUPRENORPHINE USE, AND ACCESS TO AND INTEREST IN BUPRENORPHINE TREATMENT Aaron Fox1,2; Adam Chamberlain2; Taeko M. Frost3; Chinazo Cunningham1,2. 1Montefiore Medical Center, Bronx, NY; 2Albert Einstein College of Medicine, Bronx, NY; 3Washington Heights CORNER Project, New York, NY. (Tracking ID #1927780) BACKGROUND: In the United States, the opioid addiction epidemic is escalating; however, there is a large gap (nearly 1.5 million persons) between those in need of treatment and those who receive treatment. Primary care physicians have the opportunity to address this treatment gap by offering buprenorphine maintenance therapy (BMT), but access to treatment may not be adequate to meet the current demand. Recently, diversion of buprenorphine has received major media attention, where concerns were raised about illicit buprenorphine use to get high; however, qualitative studies have suggested that opioid users may use illicit buprenorphine to "self- treat" their opioid addiction, especially if they experience barriers to BMT. This study investigated illicit buprenorphine use among syringe exchange participants, a group with high needs for opioid addiction treatment, and explored whether illicit use was associated with access to BMT and interest in initiating BMT. METHODS: Syringe exchange participants were recruited from the offices of a harm reduction agency in New York City. Computer-based interviews were conducted to determine: 1) prior use of buprenorphine (illicit and prescribed); 2) access to BMT (perceived barriers); and 3) interest in BMT (overall interest in BMT and likelihood of initiating treatment). Overall interest was measured using a 5-point Likert scale; those rating their level of interest as 4 or 5 were considered to be interested in BMT. Access to and interest in BMT were compared between illicit buprenorphine users and non-users using chi square or t-tests. RESULTS: Of 102 opioid users, 57 had used illicit buprenorphine (34 with illicit buprenorphine use only; 23 with illicit and prescribed buprenorphine use). Nine participants had used prescribed buprenorphine only. Overall, 45% of participants were interested in BMT. Regarding access, the most common barrier to BMT was, "did not know where to get treatment," which was reported by 51% of participants. Other common barriers were costs (33%) and transportation (28%). Compared to those who had never used illicit buprenorphine, not knowing where to get treatment was more common among illicit buprenorphine users (64% vs. 36%, p < 0.01),
- verall interest in BMT was greater among illicit buprenorphine users (mean ± SD; 3.37 ± 1.29 vs. 2.80 ± 1.34,